| Literature DB >> 36176583 |
Siyi Liu1, Yinhuan Ding1, Yifei Xu1, Zhaoyinqian Li1, Zhangrui Zeng1, Jinbo Liu1.
Abstract
Extensively drug-resistant and hypervirulent Klebsiella pneumoniae (XDR-hvKp) is a new problem for patients in Intensive Care Unit (ICU) and can become an even more severe threat if resistant to tigecycline, considered one of the 'last lines of defense' drugs. This study collected seven non-replicated tigecycline-resistant XDR-hvKp from seven patients and performed genome analysis and epidemiological investigation using whole genome equencing (WGS) and other methods. All strains in this study were identified as ST11-KL64 and showed high resistance to antibiotics such as β-lactams, aminoglycosides, quinolones, and tigecycline, and one strain was also resistant to colistin. All strains were determined to be hvKp by the results of serum resistance assay and Galleria mellonella infection models. All strains had resistance genes bla CTX-M-65,bla KPC-2,bla LAP-2,bla TEM-1B, rmtB, and qnrS1 and virulence factors such as rmpA, rmpA2, and aerobactin (iucABCD, iutA). The expression of the AcrAB-TolC efflux pump was upregulated in all strains, and the expression levels of the gene pmrK was significantly upregulated in colistin-resistant strain DP compared to colistin-sensitive strain WT in this study. In conclusion, we described an outbreak caused by tigecycline-resistant XDR-hvKp in the ICU of a teaching hospital in southwest China. The spread of these superbugs poses a great threat to patients and therefore requires us to closely monitor these XDR-hvKp and develop relevant strategies to combat them.Entities:
Keywords: Klebsiella pneumoniae; extensively drug-resistant; hypervirulent; outbreak; tigecycline resistance
Mesh:
Substances:
Year: 2022 PMID: 36176583 PMCID: PMC9513609 DOI: 10.3389/fcimb.2022.979219
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Clinical characteristics of patients with XDR-HvKp infection.
| Patient | DP | FY | HS | LC | WT | XY | YF |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Gender | Male | Male | Female | Male | Female | Male | Male |
| Age (years) | 27 | 88 | 82 | 82 | 56 | 79 | 74 |
| Department | ICU, hematology | ICU | ICU, internal medicine | ICU | ICU, respiratory ICU | ICU, neurosurgery unit | ICU, urology |
| Basic diseases | Acute myelocytic leukemia (M4), liver function damage | Liver function damage, cerebral infarction | Liver function damage, diabetes, kidney injury | Multiple organ failure | high blood pressure, anxiety disorders, depressive disorder | Diabetes, brain contusion | Renal pelvis tumor |
| Date of specimen collection: type | 2/13/2022: Sputum | 2/11/2022: Sputum | 2/18/2022: Sputum | 2/20/2022: Sputum | 1/26/2022: Sputum | 2/21/2022: Sputum | 2/23/2022: Sputum |
| Infection type | Pneumonia, sepsis | Pneumonia, sepsis | Pneumonia, sepsis | Pneumonia, sepsis | Pneumonia | Pneumonia | Pneumonia |
| Therapeutic antimicrobial usage | MEM, VA, VRC, SXT, TGC, CZA, ATM, COL | MEM, CZA, ATM, VRC, TCP, CPS, COL | CPS, TZP, MEM | ONZ, CPS, MEM | CPS, VRC, LZD, CZA | TZP, VA, LVX, FLC, ETM, COL | CPS |
| Temperature (Tmax) (°C) | 38.7 | 38.4 | 40 | 39 | 39.2 | 39.2 | 38.2 |
| WBC (×109/L) | 1.15 | 2.28 | 15.6 | 6.6 | 10.24 | 5.30 | 20.62 |
| PCT (ng/mL) | 7.000 | 22.750 | 7.380 | 44.950 | 0.290 | 1.440 | 4.34 |
| Invasive procedures | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Duration of ICU stay (days) | 52 | 35 | 21 | 19 | Unknown | Unknown | 5 |
| Outcomes | Died | Unknown | Died | Unknown | Treating | Treating | Unknown |
ICU, Intensive Care Unit; TZP, Piperacillin-tazobactam; CZA, Ceftazidime-avibactam; ATM, Aztreonam; MEM, Meropenem; COL, Colistin; SXT, Trimethoprim-sulfamethoxazole; TGC, Tigecycline; VA, Vancomycin; LZD, Linezolid; CPS, Cefoperazone-sulbactam; LVX, Levofloxacin; ONZ, Ornidazole; FLC, Fluconazole; TCP, Teicoplanin; VRC, Voriconazole; ETM, Etimicin; Invasive procedures , Including tracheal intubation, catheter drainage, surgery, and puncture.
Figure 1Epidemiology of seven patients in this study. Each grey broadband represents the timeline of one patient, the figure indicates the date of transfer of the patient to the new ward and the date of isolation of the strain as well as the date of the patient’s first use of this type of antibiotic in this investigation. The outcome of each patient is represented at the end of each grey broadband. The names of patients/strains are next to the pink broadband.
Antimicrobial susceptibility profiles of seven XDR-HvKp strains.
| Isolates/patients | MIC (mg/L) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TZP | CZA | FEP | ATM | IPM | MEM | COL | GM | AN | TE | CIP | SXT | C | FOS | FM | TGC | TGC + NMP | |
| WT | > 64/4 | 8/4 | 128 | > 16 | 128 | 256 | 1 | 128 | 128 | 128 | > 2 | > 4/76 | 2 | > 256 | 128 | 8 | 0.5 |
| FY | > 64/4 | 8/4 | 128 | > 16 | 128 | 256 | 1 | 128 | 128 | 128 | > 2 | > 4/76 | 2 | > 256 | 128 | 8 | 0.5 |
| DP | > 64/4 | 8/4 | 128 | > 16 | 128 | 256 | 4 | 128 | 128 | 128 | > 2 | > 4/76 | 2 | > 256 | 128 | 8 | 0.5 |
| HS | > 64/4 | 8/4 | 128 | > 16 | 128 | 256 | 1 | 128 | 128 | 128 | > 2 | > 4/76 | 2 | > 256 | 128 | 8 | 0.5 |
| XY | > 64/4 | 8/4 | 128 | > 16 | 128 | 256 | 1 | 128 | 128 | 128 | > 2 | > 4/76 | 2 | > 256 | 128 | 8 | 0.5 |
| YF | > 64/4 | 8/4 | 128 | > 16 | 128 | 256 | 1 | 128 | 128 | 128 | > 2 | > 4/76 | 2 | > 256 | 128 | 8 | 0.5 |
| LC | > 64/4 | 8/4 | 128 | > 16 | 128 | 256 | 1 | 128 | 128 | 128 | > 2 | > 4/76 | 2 | > 256 | 128 | 8 | 0.5 |
TZP, Piperacillin-tazobactam; CZA, Ceftazidime-avibactam; FEP, Cefepime; ATM, Aztreonam; IPM, Imipenem; MEM, Meropenem; COL, Colistin; GM, Gentamicin; AN, Amikacin; TE, Tetracycline; CIP, Ciprofloxacin; SXT, Trimethoprim-sulfamethoxazole; C, Chloramphenicol; FOS, Fosfomycin; FM, Nitrofurantoin; TGC, Tigecycline; NMP, 1-(1-Naphthylmethyl)-piperazine, 100 mg/L.
Figure 2Virulence phenotypes of seven XDR-hvKp strains. (A) Survival curves of the Galleria mellonella larvae. (B) Activity of strains in serum from healthy human. The data are expressed as the Mean ± SE (standard error).In (A, B), K. pneumoniae NTUH-K2044 and ATCC 700603 were used as positive control and negative control, respectively.
Figure 3Phylogenetic tree of seven XDR-hvkp and K. pneumoniae ATCC 13883 based on OrthoANI values; K. pneumoniae ATCC 13883 was used as a control. The value on the branch, not the length of the branch in the graph, represents the real physical length of the branch.
Figure 4(A) Comparison of sequences surrounding bla KPC-2 between strains in this study and strain PKPHS2 (CP003224). (B) Comparison of sequences related to virulence among strains in this study, Pkp12-vir (CP082766), and NTUH-K2044 (AP006726). (C) Schematic representation of the insertion of the acrR gene by ISkpn26. In (A–C), as all strains in this study showed almost identical results to those of the studies mentioned above, we show only a graphical representation of one of the seven strains at random. Grey shading indicates >99% identity between sequences.
Expression of acrA, acrB, ramA, soxS, marA, acrR of seven XDR-HvKp strains.
| Isolation | Relative expression | |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| ATCC13883 | 1 | 1 | 1 | 1 | 1 | 1 |
| WT | 2.90 ± 0.33*** | 2.78 ± 0.17***
| 9.40 ± 1.73** | 1.11 ± 0.08NO | 0.94 ± 0.07 NO | 0.20 ± 0.03*** |
| FY | 2.93 ± 0.30*** | 2.77 ± 0.31*** | 9.61 ± 1.22*** | 1.06 ± 0.15 NO | 1.04 ± 0.08 NO | 0.17 ± 0.03*** |
| DP | 2.74 ± 0.31*** | 2.32 ± 0.28** | 7.33 ± 0.34*** | 1.07 ± 0.10 NO | 0.93 ± 0.15 NO | 0.19 ± 0.02*** |
| HS | 2.87 ± 0.55** | 2.81 ± 0.35*** | 10.08 ± 0.77*** | 1.22 ± 0.39 NO | 0.90 ± 0.13 NO | 0.24 ± 0.01*** |
| LC | 2.47 ± 0.26*** | 2.71 ± 0.56** | 10.54 ± 0.55*** | 1.13 ± 0.13 NO | 0.91 ± 0.14 NO | 0.14 ± 0.02*** |
| XY | 2.68 ± 0.33*** | 2.51 ± 0.23*** | 9.14 ± 1.20*** | 1.01 ± 0.16 NO | 1.11 ± 0.15 NO | 0.11 ± 0.02*** |
| YF | 2.62 ± 0.31*** | 2.90 ± 0.42** | 11.23 ± 0.86*** | 1.02 ± 0.17 NO | 1.06 ± 0.16 NO | 0.31 ± 0.04*** |
Relative expression compared with K. pneumoniae ATCC13883 (expression = 1); Results are means of 3 runs ± standard deviation.
*P<0.05; **P<0.01; ***P<0.001 (p value vs. K. pneumoniae ATCC13883) by two-tailed unpaired t test; NO, no significance by two-tailed unpaired t test.
Figure 5Comparison between the relative expression levels of the phoP, phoQ, pmrC, pmrA, pmrB, pmrK, and pmrD genes in strain DP and strain WT (Relative expression compared with K. pneumoniae ATCC13883, expression = 1). Values of relative expression are expressed as means and the standard deviation from experiments which were repeated in triplicate independently. *P<0.05; **P<0.01; ***P<0.001 by two-tailed unpaired t test; ns, no significance by two-tailed unpaired t test.